A Widely Used HIV Drug Shows Reassuring Weight Data in Young People
Dolutegravir has become one of the most important medicines in modern HIV care. It is potent, easy to take and widely recommended for adults, adolescents and children. But as its use has expanded, so have questions about possible weight gain, particularly after reports from adult studies.
A large international study of children and adolescents living with HIV now offers a largely reassuring answer. Drawing on routine clinical data from 15 cohorts across Europe and Thailand, the investigators followed 948 young people aged 2 to 17 years who started dolutegravir. Weight development was assessed using body-mass-index-for-age, a measure that accounts for normal growth during childhood and adolescence.
The study found that body-mass-index-for-age increased after starting dolutegravir, but the average change was small. Over 96 weeks, the increase was similar to that seen in young people treated with protease inhibitor–based HIV regimens. This is an important finding: it suggests that dolutegravir, despite concerns raised in adults, is not clearly associated with major excess weight gain in children and adolescents compared with other established HIV treatments.
The results are not a reason to ignore weight. Some groups gained more than others, including children aged 6 to 11 years, those receiving tenofovir alafenamide, those with lower weight at the start, and some sex and ethnicity subgroups. A proportion of children who began in the normal-weight range moved into the overweight category during follow-up. For clinicians, the message is therefore balanced: dolutegravir remains a highly valuable HIV drug, but weight, blood pressure, lipids and other metabolic risk factors should be followed as part of routine care.
The broader significance of the study lies in the power of long-term cohort research. Questions about treatment safety often emerge only after drugs are used widely in real life, outside clinical trials. Large cohort collaborations make it possible to detect these patterns, distinguish small changes from clinically meaningful signals, and identify which patients may need closer follow-up.
This is exactly why infrastructures such as the Swiss HIV Cohort Study are so important. They provide the long-term, high-quality clinical data needed to understand how HIV treatment affects people over years and decades. For patients, this means that care is not guided only by trials performed under ideal conditions, but also by careful observation of what happens in everyday medicine.